SCHEMBL13429372

SCHEMBL13429372

CC(C)(C)CNc1ccc(CNc2cccc(Oc3cc(=O)[nH]c4ccccc34)c2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
GAA P10253 1/20 0.39
KMT2A Q03164 1/20 0.39
AR P10275 3/20 0.38
BRAF P15056 7/20 0.36
GRM5 P41594 1/20 0.36
HDAC1 Q13547 1/20 0.36
MAPT P10636 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
LMNA P02545 1/20 0.36
HTT P42858 1/20 0.36
CACNA1B Q00975 1/20 0.36
PTK6 Q13882 1/20 0.35
APP P05067 1/20 0.35
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429367 0.87 HDAC1 (0.43) MEN1GAAKMT2ABRAFHDAC1
SCHEMBL13429319 0.86 MEN1 (0.45) MEN1GAAKMT2AGRM5HDAC1
SCHEMBL13429368 0.84 MEN1 (0.42) MEN1GAAKMT2ABRAFGRM5
SCHEMBL3221532 0.84 GAA (0.41) MEN1GAAKMT2ABRAFGRM5
SCHEMBL3227033 0.84 MEN1 (0.40) MEN1GAAKMT2AARBRAF
SCHEMBL13429362 0.84 CACNA1B (0.41) MEN1GAAKMT2ABRAFGRM5
SCHEMBL13429366 0.82 MEN1 (0.43) MEN1GAAKMT2AARBRAF
SCHEMBL3219003 0.81 BRAF (0.48) MEN1GAAKMT2AARBRAF
SCHEMBL3214639 0.81 SMN1; SMN2 (0.49) MEN1GAAKMT2ABRAFMAPT
SCHEMBL3214363 0.80 CYP1A2 (0.44) MEN1GAAKMT2ABRAFGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS WYETH (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068204-A1 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS MTOR, RICTOR, PIK3CA MEN1 2648/4885GAA 1227/4885KMT2A 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.